Skip to main content
. 2014 Oct;34(19):3702–3720. doi: 10.1128/MCB.00099-14

FIG 10.

FIG 10

Gain in tumor size with loss of Jmjd1a is rescued by loss of G9a. (A) Western blot analysis of Jmjd1a KO ES cells stably transfected with G9a shRNA (independent cell lines #1 and #2) shows decreased G9a protein expression. (B) Morphological appearance of tumors resected from NOD-SCID mice 24 days after subcutaneous injection of Jmjd1a KO ES cells expressing either control or G9a shRNA. (C) Final tumor masses of Jmjd1a KO tumors with either control or G9a shRNA knockdown formed after 24 days of growth. (D) Antiangiogenic genes were upregulated in Jmjd1a KO + G9a KD tumors. Gene expression levels were normalized against the Ywhaz reference gene, and the fold change over the Jmjd1a KO + Control KD was calculated. *, P < 0.05. (E) Morphological appearance of tumors resected from NOD-SCID mice 20 days after subcutaneous injection of wild-type ES cells pretreated either with control (DMSO only) or with 1 μM BIX-01294-containing medium. (F) Final masses of wild-type tumors following treatments as described for panel E. (G) Morphological appearance of tumors resected from NOD-SCID mice 20 days after subcutaneous injection of Jmjd1a-deficient ES cells pretreated either with control (DMSO only) or with 1 μM BIX-01294-containing medium. (H) Final masses of Jmjd1a-deficient tumors under the same treatment conditions as for panel G.